Lu Kang Pharmaceutical: Plans to invest 194 million yuan in the construction of a continuous intelligent manufacturing project for chemical APIs.

LuKang Pharmaceutical announced that the company plans to invest 194 million yuan to establish a continuous intelligent manufacturing project for chemical raw materials. The aim is to enhance the scale and profitability of raw materials and to build a low-cost production model integrating intermediates, raw materials, and formulations. The project will involve the construction of a multifunctional raw material workshop, a material storage tank area, and accompanying auxiliary facilities, with the construction site located in the company's biomedical circular economy industrial park. The construction period is expected to be 18 months. This investment was approved at the 15th meeting of the 11th Board of Directors on August 5, 2026, and does not require approval from the shareholders' meeting. It does not constitute a related party transaction or a major asset restructuring. The project has completed preliminary feasibility studies and project initiation work, and will subsequently carry out the filing and application work for safety assessments, environmental assessments, and energy assessments as part of the "three simultaneous" procedures.